Literature DB >> 12019216

Molecular pathophysiology in Tay-Sachs and Sandhoff diseases as revealed by gene expression profiling.

Rachel Myerowitz1, Douglas Lawson, Hiroki Mizukami, Yide Mi, Cynthia J Tifft, Richard L Proia.   

Abstract

Tay-Sachs and Sandhoff diseases are lysosomal storage disorders characterized by the absence of beta-hexosaminidase activity and the accumulation of GM2 ganglioside in neurons. In each disorder, a virtually identical course of neurodegeneration begins in infancy and leads to demise generally by 4-6 years of age. Through serial analysis of gene expression (SAGE), we determined gene expression profiles in cerebral cortex from a Tay-Sachs patient, a Sandhoff disease patient and a pediatric control. Examination of genes that showed altered expression in both patients revealed molecular details of the pathophysiology of the disorders relating to neuronal dysfunction and loss. A large fraction of the elevated genes in the patients could be attributed to activated macrophages/microglia and astrocytes, and included class II histocompatability antigens, the pro-inflammatory cytokine osteopontin, complement components, proteinases and inhibitors, galectins, osteonectin/SPARC, and prostaglandin D2 synthase. The results are consistent with a model of neurodegeneration that includes inflammation as a factor leading to the precipitous loss of neurons in individuals with these disorders.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12019216     DOI: 10.1093/hmg/11.11.1343

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  40 in total

Review 1.  Enzymes of the cyclooxygenase pathways of prostanoid biosynthesis.

Authors:  William L Smith; Yoshihiro Urade; Per-Johan Jakobsson
Journal:  Chem Rev       Date:  2011-09-27       Impact factor: 60.622

Review 2.  Glycosphingolipidoses: beyond the enzymatic defect.

Authors:  Annick Raas-Rothschild; Irene Pankova-Kholmyansky; Yaacov Kacher; Anthony H Futerman
Journal:  Glycoconj J       Date:  2004       Impact factor: 2.916

Review 3.  Astrocytes and lysosomal storage diseases.

Authors:  K V Rama Rao; T Kielian
Journal:  Neuroscience       Date:  2015-05-30       Impact factor: 3.590

Review 4.  Fig4 deficiency: a newly emerged lysosomal storage disorder?

Authors:  Colin Martyn; Jun Li
Journal:  Prog Neurobiol       Date:  2012-11-16       Impact factor: 11.685

5.  AAV-mediated gene delivery attenuates neuroinflammation in feline Sandhoff disease.

Authors:  Allison M Bradbury; Tiffany A Peterson; Amanda L Gross; Stephen Z Wells; Victoria J McCurdy; Karen G Wolfe; John C Dennis; Brandon L Brunson; Heather Gray-Edwards; Ashley N Randle; Aime K Johnson; Edward E Morrison; Nancy R Cox; Henry J Baker; Miguel Sena-Esteves; Douglas R Martin
Journal:  Neuroscience       Date:  2016-10-26       Impact factor: 3.590

Review 6.  Pathology and current treatment of neurodegenerative sphingolipidoses.

Authors:  Matthias Eckhardt
Journal:  Neuromolecular Med       Date:  2010-08-22       Impact factor: 3.843

Review 7.  In Vivo NMR Studies of the Brain with Hereditary or Acquired Metabolic Disorders.

Authors:  Erica B Sherry; Phil Lee; In-Young Choi
Journal:  Neurochem Res       Date:  2015-11-26       Impact factor: 3.996

8.  Upregulation of proinflammatory cytokines in the fetal brain of the Gaucher mouse.

Authors:  Young Bin Hong; Eun Young Kim; Sung-Chul Jung
Journal:  J Korean Med Sci       Date:  2006-08       Impact factor: 2.153

9.  Possible role of autoantibodies in the pathophysiology of GM2 gangliosidoses.

Authors:  Akira Yamaguchi; Kayoko Katsuyama; Kiyotaka Nagahama; Toshiyuki Takai; Ichiro Aoki; Shoji Yamanaka
Journal:  J Clin Invest       Date:  2004-01       Impact factor: 14.808

10.  Increased expression of monocyte CD44v6 correlates with the deveopment of encephalitis in rhesus macaques infected with simian immunodeficiency virus.

Authors:  Maria Cecilia G Marcondes; Caroline M S Lanigan; Tricia H Burdo; Debbie D Watry; Howard S Fox
Journal:  J Infect Dis       Date:  2008-06-01       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.